KRAS and pancreatic neoplasm: They went on to evaluate the effect of knocking out tumor cell-specific EphA2 in a mouse model of pancreatic cancer bearing a Kras G12D mutation, loss of Tp53, and a YFP marker (KPCY) and found that EphA2 knockout (KO) significantly increased T-cell infiltration and activation, as we had observed in our murine model of NSCLC.